hers wegovy - Search News

Hims & Hers Stock Drops

Hosted on MSN · 1d

Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.

Investopedia on MSN · 1d

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Eli Lilly’s Wegovy and Novo Nordisk’s Ozempic has been resolved.

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

11don MSN

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...

12d

Super Bowl ad sparks controversy over cut-rate Wegovy alternative

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

12d

GLP-1 ad battle—Ozempic and Wegovy maker responds to Hims & Hers Super Bowl debut

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

24/7 Wall St. on MSN1d

Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?

Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results